首页> 外文期刊>Scientific reports. >Vitamin K supplementation during pregnancy for improving outcomes: a systematic review and meta-analysis
【24h】

Vitamin K supplementation during pregnancy for improving outcomes: a systematic review and meta-analysis

机译:维生素K在怀孕期间补充改善结果:系统审查和荟萃分析

获取原文
       

摘要

To study supplementation effect of vitamin K (VK) alone or combined with other nutrients administered to pregnant women, we searched Cochrane Pregnancy and Childbirth Group’s Trials Register (till 22 January 2016, updated on 28 February 2018) including other resources. Two review authors independently assessed randomised or quasi-randomised controlled trials for inclusion, data extraction, accuracy, and risk of bias. We included older trials from high-income countries (six; 21,493 women-newborns), judged mostly as high or unclear bias risk. We could not assess high-risk e.g. epileptic women, but healthy women (different gestational ages) received varying VK dosages and duration. We meta-analysed neonatal bleeding (RR 1.16, 95% CI 0.59 to 2.29; P?=?0.67) and maternal plasma VK1 (MD 2.46, 95% CI 0.98 to 3.93; P?=?0.001). We found many outcomes were un-assessed e.g. perinatal death, maternal bleeding, healthcare utilization. Mostly newborns were included where VK found significantly effective for e.g. serum VK (mother-newborn), maternal breast milk VK. Few trials reported neonatal adverse side effects. The GRADE evidence quality was very low i.e. neonatal bleeding, neonatal jaundice, maternal plasma VK1. The intervention was favourable for maternal sera VK1 but remained uncertain for neonatal bleeding and other outcomes. The existing literature gaps warrant future investigations on un-assessed or inadequately reported outcomes.
机译:为了研究维生素K(VK)单独的补充效果或与孕妇给予的其他营养素合并,我们搜索了Cochrane怀孕和分娩小组的试验登记册(直到2016年1月22日,2018年2月28日更新)包括其他资源。两次审查作者独立评估随机或准随机对照试验,以包含,数据提取,准确性和偏倚风险。我们包括高收入国家(六名; 21,493名妇女新生儿)的较旧试验,主要是高或不明确的偏见风险。我们无法评估高风险。癫痫妇女,但健康的女性(不同的妊娠期)接受了不同的VK剂量和持续时间。我们在荟萃分析的新生儿出血(RR 1.16,95%CI 0.59至2.29; p?= 0.67)和母体等离子体Vκ1(MD 2.46,95%CI 0.98至3.93; P?= 0.001)。我们发现许多结果是未评估的。围产期死亡,产妇出血,医疗利用。大多是新生儿被包括在vk的情况下,发现VK为例如明显有效。血清vk(母亲新生儿),母体母乳牛奶vk。少数试验报告了新生儿不良副作用。等级证据质量非常低,即新生儿出血,新生儿黄疸,母体等离子体VK1。干预措施是有利于母体血清VK1,但对新生儿出血和其他结果保持不确定。现有的文献差距保证未来关于未评估或不充分报告的结果的调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号